The Korean Dementia Society is urging the South Korean government to expand insurance coverage for MRI scans and consultation fees to facilitate the rollout of Disease-Modifying Therapies (DMTs). This shift aims to move dementia care from symptom management to early biological intervention for eligible patients.
For decades, dementia treatment was largely palliative, focusing on slowing the decline of cognitive functions. Though, the emergence of monoclonal antibodies—drugs designed to target the underlying pathology of the brain—has created a clinical crossroads. To utilize these therapies, patients require precise biomarkers, typically identified through PET scans or cerebrospinal fluid (CSF) analysis and high-resolution MRI to monitor for safety risks. Without government-subsidized reimbursement (수가), the financial burden of these diagnostics falls on the patient, creating a systemic barrier to a potentially transformative class of medicine.
In Plain English: The Clinical Takeaway
- From “Slowing” to “Changing”: Recent treatments aim to remove the “trash” (plaques) from the brain rather than just treating the memory loss.
- The Diagnosis Gap: You cannot start these new drugs without an MRI or special scan to prove you have the specific type of protein buildup they target.
- The Cost Barrier: Current insurance systems in Korea may not cover the expensive tests needed to qualify for these new medications.
The Mechanism of Action: Targeting Amyloid-Beta Plaques
The “Disease-Modifying Therapies” (DMTs) mentioned by the Korean Dementia Society primarily refer to anti-amyloid monoclonal antibodies. These are lab-engineered proteins designed to bind to and clear amyloid-beta (Aβ) plaques—clumps of protein that accumulate in the brain and disrupt cell-to-cell communication in Alzheimer’s disease.
The mechanism of action (the specific biochemical interaction through which a drug produces its effect) involves the drug tagging these plaques for removal by the brain’s own immune cells, known as microglia. By reducing the plaque burden, these therapies aim to slow the rate of cognitive decline in patients with early-stage Alzheimer’s or Mild Cognitive Impairment (MCI).
However, this process is not without risk. The most significant concern is ARIA (Amyloid-Related Imaging Abnormalities), which can manifest as edema (swelling) or microhemorrhages (tiny bleeds) in the brain. This is why the Korean Dementia Society is emphasizing the need for subsidized MRI monitoring. without regular imaging, ARIA can proceed undetected, leading to severe neurological complications.
Global Regulatory Landscapes and Patient Access
South Korea’s struggle with reimbursement mirrors global tensions between medical innovation and healthcare economics. In the United States, the FDA granted traditional approval to drugs like lecanemab, but the Centers for Medicare & Medicaid Services (CMS) initially restricted coverage until strict diagnostic criteria were met. This created a “geographic lottery” where only wealthy patients could afford the necessary PET scans to qualify for the drug.
Similarly, the European Medicines Agency (EMA) has been more cautious, with some member states rejecting these therapies due to a perceived lack of significant clinical benefit relative to the high cost and risk of ARIA. The UK’s NHS continues to evaluate the cost-effectiveness of these treatments through the NICE framework, emphasizing that the “benefit” must outweigh the systemic cost of the required diagnostic infrastructure.
“The challenge is no longer just about developing a molecule that works in a trial, but about building a healthcare delivery system that can actually identify the right patient at the right time without bankrupting the provider or the patient.” — Dr. Maria Carrera, Neuro-epidemiologist and Public Health Consultant.
Clinical Efficacy vs. Diagnostic Requirements
To understand why the Korean Dementia Society is calling for a paradigm shift, we must examine the data. Most Phase III trials for these DMTs show a statistically significant slowing of decline, but the absolute difference in daily functioning can be modest. The “value” of the drug is heavily dependent on early detection.
| Metric | Traditional Symptomatic Care | Disease-Modifying Therapy (DMT) |
|---|---|---|
| Primary Goal | Manage symptoms (e.g., Cholinesterase inhibitors) | Clear amyloid plaques from brain tissue |
| Target Population | All stages of dementia | Early-stage / Mild Cognitive Impairment (MCI) |
| Diagnostic Requirement | Clinical cognitive assessment | Amyloid-PET or CSF Biomarkers + Baseline MRI |
| Key Risk | Gastrointestinal issues, insomnia | ARIA (Brain swelling/micro-bleeds) |
Funding for these pivotal trials has been predominantly driven by pharmaceutical giants (such as Eisai and Biogen). Even as the research is robust, the commercial interest in high-cost therapies often clashes with the public health goal of universal access. This is the “information gap” in the current Korean discourse: the transition from a clinical trial success to a sustainable public health policy.
Contraindications & When to Consult a Doctor
DMTs are not suitable for all patients. They are strictly contraindicated for individuals with a history of severe hemorrhagic stroke or those taking potent anticoagulant medications (blood thinners), as these significantly increase the risk of fatal brain bleeds during plaque clearance.
Patients and caregivers should consult a neurologist immediately if they notice:
- Sudden onset of confusion or severe headaches following infusion.
- New-onset seizures or focal neurological deficits (e.g., weakness on one side of the body).
- Rapidly progressing cognitive decline that deviates from the expected trajectory of the disease.
The Path Toward Precision Neurology
The demand for MRI and consultation subsidies is more than a financial request; it is a demand for a shift toward precision neurology. By integrating high-resolution imaging into the standard of care, South Korea can move toward a model where dementia is treated as a biological failure to be corrected, rather than an inevitable decline to be managed.
If the government adopts these recommendations, the focus will shift toward “secondary prevention”—identifying those in the earliest stages of protein accumulation and intervening before irreversible neuronal death occurs. This trajectory aligns with the WHO’s Global Action Plan on the Public Health Response to Dementia, which prioritizes early diagnosis and integrated care.
References
- PubMed – National Library of Medicine (Amyloid-beta clearance and ARIA clinical data)
- The Lancet (Global prevalence and epidemiological trends in Alzheimer’s)
- JAMA – Journal of the American Medical Association (Phase III trial results for monoclonal antibodies)
- World Health Organization (WHO) (Guidelines on dementia care and public health)
